الفهرس Only 14 pages are availabe for public view
 |  | from | 107 |  |  |
| | | from | 107 | | |
Abstract
In the last decade, understanding of premenstrual disorders has
undergone a transformation. Premenstrual syndrome (PMS) is now
viewed as a complex psychoneuroendocrine disorder that is known to
affect women’s emotional and physical well-being. PMS is no longer
considered a single condition, but a group of menstrually related disorders
and symptoms. Broadly defined, PMS is the constellation of emotioni,
behavioral and physical symptoms that occur during the prmenstrual
(luteal) phase of the menstrual cycle and resolve after the start of menses.
Premenstrual symptoms sufficient to impair daily life and relationships
are estimated to affect up to 40% of women of reproductive age.
Approximately 5% of these women suffer from premenstrual dysphoric
disorder (PMDD), a severe form of PMS marked by adverse mood
symptoms .
As regarding the previously mentioned knowledge, this thesis study
was conducted to compare between the use of Progesterone, Propranolol
and Prozac in treatment of PMS. 100 patients were included in the study
and they were subdivided into 4 groups:
Group (1): 25 patients received progesterone & propranolol in the form
of uterogestan cap 100 mg + inderal tab 40 mg twice daily
one week before onset of the cycle.
Group (2): 25 patients received progesterone in the form of utrogestan
cap 100 mg twice daily one week before onset of the cycle.
Group (3): 25 patients received Prozac in the form of Prozac tab 20 mg
twice daily one week before onset of the cycle.
Group (4): 25 patients received propranolol in the form of inderal tab 40
mg twice daily one week before onset of the cycle .
This study differs from other studies in some points as,